56 results
8-K
EX-99.1
ARAV
Aravive Inc
25 May 23
Regulation FD Disclosure
5:00pm
or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that batiraxcept may cause
8-K
EX-99.1
ARAV
Aravive Inc
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
especially in light of the COVID-19 pandemic; the risk that batiraxcept may cause serious side effects or have properties that delay or prevent regulatory
8-K
EX-99.1
ARAV
Aravive Inc
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
or enrolling patients especially in light of the COVID-19 pandemic; the risk that batiraxcept may cause serious side effects or have properties that delay
8-K
EX-99.1
ARAV
Aravive Inc
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am
especially in light of the COVID-19 pandemic; the risk that batiraxcept may cause serious side effects or have properties that delay or prevent
8-K
EX-99.1
sp9rwh 1f
10 Nov 22
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
EX-99.1
d7rvzn2nyfnkozj
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-99.1
5r2y ggnr3
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
mbb69ntry712cy b2
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
EX-99.1
e71hy
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
424B5
xpmh9i8rklw5zy gyu
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
mdtzt
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
EX-99.1
ke4smzg1pdises329
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
z4674gg
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
424B3
r60t0 tzoetu6uvh
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-99.1
syxbtfws f4hupj
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am